International Drugmakers Plan for Higher Costs as Brexit Looms

International Pharmaceutical Regulatory Monitor
A A
Testifying before a UK House of Commons committee last month, international pharmaceutical companies said they are already hedging their bets when it comes to the real-world consequences of Brexit, making preparations for new hurdles in manufacturing and duplications of batch release testing that could cost millions of pounds per year.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor